BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

DCPH has been the topic of a number of other reports. JPMorgan Chase & Co. initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an overweight rating and a $30.00 price objective on the stock. Instinet initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. JMP Securities initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an outperform rating and a $38.00 price objective on the stock. Zacks Investment Research lowered shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, January 15th. Finally, Nomura initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Deciphera Pharmaceuticals currently has an average rating of Buy and an average target price of $40.83.

Deciphera Pharmaceuticals (DCPH) opened at $28.92 on Friday. Deciphera Pharmaceuticals has a 1 year low of $15.15 and a 1 year high of $29.48.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($5.30). analysts anticipate that Deciphera Pharmaceuticals will post -2.91 earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. American International Group Inc. purchased a new position in Deciphera Pharmaceuticals in the 4th quarter valued at $126,000. SG Americas Securities LLC purchased a new position in Deciphera Pharmaceuticals in the 3rd quarter valued at $143,000. FNY Managed Accounts LLC purchased a new position in Deciphera Pharmaceuticals in the 3rd quarter valued at $153,000. The Manufacturers Life Insurance Company purchased a new position in Deciphera Pharmaceuticals in the 4th quarter valued at $179,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in Deciphera Pharmaceuticals in the 4th quarter valued at $288,000. Hedge funds and other institutional investors own 44.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Deciphera Pharmaceuticals (DCPH) Rating Increased to Strong-Buy at BidaskClub” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2018/02/14/deciphera-pharmaceuticals-dcph-rating-increased-to-strong-buy-at-bidaskclub.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.